Development of peptide inhibitor as a therapeutic agent against head and neck squamous cell carcinoma (HNSCC) targeting p38α MAP kinase

• Published in: Biochimica et biophysica acta. General subjects Vol. 1830; no. 3; pp. 2763 - 2769
• Main Authors: Gill, Kamaldeep, Singh, Abhay K., Kapoor, Vaishali, Nigam, Lokesh, Kumar, Rahul, Holla, Prasida, Das, Satya N., Yadav, Savita, Subbarao, Naidu, Mohanti, Bidhu K., Dey, Sharmistha
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.03.2013
• Subjects: active sites; adenosine triphosphate; Anticancer; antineoplastic agents; Apoptosis; binding sites; blood proteins; caspase-3; cell differentiation; cell growth; enzyme-linked immunosorbent assay; flow cytometry; head; HNSCC; humans; inflammation; inhibitory concentration 50; interleukin-1beta; mitogen-activated protein kinase; molecular models; mouth neoplasms; p38α; patients; squamous cell carcinoma; surface plasmon resonance; Tetrapeptide; tumor necrosis factor-alpha; viability; RU; RPC; HRP; MHC; DLS; TFA; NPP; p38α; SPR; Tetrapeptide; MKKK; HBTU; DMF; SP; PBS; HTVS; MAPK; MKK; ATF; HNSCC; LB; IPTG; XP; PI; Anticancer; Apoptosis

The p38α MAP kinase pathway is involved in inflammation, cell differentiation, growth, apoptosis and production of pro-inflammatory cytokines TNF-α and IL-1β. The overproduction of these cytokines plays an important role in cancer. The aim of this work was to design a peptide inhibitor on the basis...